Hence, we believe that HNF-1β inhibitors may be a future therapeutic strategy to improve the prognosis of OCCC patients, and the energy metabolism of tumor cells might direct us to future OCCC targeting research (Fig. 4C). Here, HNF1B is linked to neoplasm.